Solubilization of an hydrophobic API for anti-cancer treatment

Poor water solubility is one of the most significant barrier limiting drug development. Indeed, more than 40% of compounds identified through combinatorial screening programs display poor aqueous solubility, which is associated with poor bioavailability, suboptimal dosing, etc.

Adjuvatis uses a safe-by-design technology that allows formulation of APIs with little or no solubility. Adjuvatis develops biocompatible and biodegradable formulations with high tolerance, which adapt to your APIs, study models and therapeutic areas.

We were very happy to work with Université Côte d’Azur, CNRS, IPMC, to overcome solubility and biodegradability issues related to the development of a small molecule from marine sponge, panicein A hydroquinone (PAH). As recently published in Cancers, this drug was formulated with i-Particles leading to their solubilisation and protection from in vivo oxidation. In mice, this formulation was able to increase cytotoxic effectiveness of an anti-cancer drug against drug-resistant melanoma cells.